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osting by EAbstract Objective: To investigate the potential effects of eleven of the most commonly used
Saudi folk herbal medications on the metabolic activity of CYP2C9 in human liver microsomes.
Method: CYP2C9-mediated 40-hydroxylation of tolbutamide (TB) to 40-hydroxytolbutamide (4-
OH-TB) was utilized to assess the metabolic activity of CYP2C9. In the present study, an initial
screening of the eleven herbs was carried out by incubating TB with microsomes and NADPH in
absence or presence of a ﬁxed concentration (25 lg/ml) of alcoholic extracts of different herbs
and the metabolite formed was measured by HPLC. Herbs that showed signiﬁcant effects were fur-
ther investigated at a lower range of concentration.
Results: Among the investigated herbal extracts, only aniseed and curcuma showed statistically sig-
niﬁcant effects on the formation of 4-OH-TB in human liver microsomes. Curcuma produced a
potent inhibition on the metabolite formation and its maximum (about 45% inhibition) was
observed at the highest extract concentrations (10 and 25 lg/ml). On the other hand, aniseed signif-
icantly activates the formation of 4-OH-TB and the maximum activation (about 55%) was observed
at 2.5 lg/ml of aniseed extract.
Conclusion: The results of this study have shown that alcoholic extracts of curcuma and aniseed
were capable of inhibiting and activating; respectively, the CYP2C9-mediated 4-OH-TB formation
in human liver microsomes, suggesting that these herbs have the potential to interact with CYP2C9
drug substrates. None of the other nine investigated herbs was able to produce any statistically sig-
niﬁcant effect.
ª 2010 King Saud University. All rights reserved.ity. All rights reserved. Peer-
d University.
lsevier1. Introduction
Use of herbal products has increased steadily among adults
over the past few years. In fact, many people think that all
herbs are safe owing to their natural origin. However, herbs
may interact with conventional medications either taken as
over the counter or prescribed by physicians resulting in
168 F.I. Al-Jenoobivarious side effects (Klepser and Klepser, 1999; Izzo and
Ernst, 2001). Such interactions may result in a new side effect
that is not seen with the use of the herb or drug alone (Bailey
and Dresser, 2004; Jankel and Fitterman, 1993). In United
States of America, it was reported that about one third of
people were using at least one type of alternative therapy
(Eisenberg et al., 1993). In some other countries the propor-
tions of patients who were using alternative medicine over
one year were about 23% in Denmark, 49% in France,
48.5% in Australia and 24% in Saudi Arabia (Ioannides,
2002; Maclennan et al., 1996; Fisher and Ward, 1994;
Al-Rowais, 2002).
A number of studies have reported many herbal product-
drug interactions (Huang and Lesko, 2004). Some of the recent
investigations have suggested the modulation of cytochrome P-
450 enzymes (CYP)-mediated drug elimination as amajormech-
anism responsible for such types of interactions (Gurley et al.,
2002; David et al., 2002). CYP2C9 has been considered as one
of the most important drug-metabolizing enzymes in human
judging by the number of substratesmetabolized by this enzyme,
which include nonsteroidal anti-inﬂammatory drugs, hypogly-
cemic agents and some narrow therapeutic index drugs such as
(S)-warfarin and phenytoin. CYP2C9 has been shown to be
polymorphic and different variants of the enzyme have been
identiﬁed (Lee et al., 2002). Its genetic polymorphism is believed
to contribute to the high inter-individual variability in the phar-
macokinetics of some of its substrates.
Although there have been many reports on food-drug and
herb-drug interactions by modulation of drug metabolism,
most of these studies have focused on CYP3A4 enzyme (Dia-
mond et al., 2000; Galluzzi et al., 2000; Guyonnet et al., 2000;
Yang et al., 2001; Zhou et al., 2004; Hermann et al., 2002;
Gross et al., 1999; Fuhr et al., 2002; Goho, 2001; Libersa
et al., 2000; Lilja et al., 2000) and only few reports are avail-
able on the role of CYP2C9 in such interactions. One study
has reported that pomegranate juice inhibits human CYP2C9
activity in vitro (Nagata et al., 2007). Recently, pine-apple juice
was found to signiﬁcantly inhibit CYP2C9 enzyme in human
microsomes (Hidaka et al., 2008). Beside fruit juices, there
are few reports wherein activity of CYP2C9 enzyme was mod-
iﬁed by certain herbal constituents. For instance, polysaccha-
ride peptides from COV-1 strain of Coriolus versicolor
inhibited tolbutamide (TB) 4-hydroxylation in rats both
in vitro and in vivo (Yeung et al., 2006). Ginkgo biloba extract
was shown to modify hypoglycemic action of tolbutamide via
competitive inhibition of (S)-warfarin 7-hydroxylase in rat
liver microsomes (Sugiyama et al., 2004). Treatment with
Angelica dahurica root extract inhibited the metabolism of
tolbutamide, nifedipine and bufuralol in rats (Ishihara et al.,
2000).
In addition to the limited availability of herb-drug interac-
tion studies involving CYP2C9, there is a lack of information
about the potential interactions between the commonly used
herbal medications in Saudi Arabia and conventional drugs.
One study has shown that the active ingredient of curcuma,
cucumin, was able to inhibit the metabolic activities of several
human recombinant CYP enzymes including CYP2C9
(Appiah-Opong et al., 2007). Therefore, the objective of this
study was to investigate the potential effects of eleven of the
most commonly used Saudi folk herbal products on the meta-
bolic activity of CYP2C9 in human liver microsomes using TB
as a probe substrate. The investigated herbs are boswellia,myrrh, asafoetida, curcuma, ginger, aloe, fenugreek, black
seed, garden cress, cumin and aniseed.2. Materials and methods
2.1. Materials
Human liver microsomes (protein concentration: 20 mg/ml)
were purchased from Human Biologics International, Inc.,
Scottsdale, USA), shipped in small vials, on dry ice and stored
at 80 C. NADPH was purchased from Helix Pomatia, ICN
Biomedicals Inc., Costa Mesa, AC, USA. Tolbutamide and
4-hydroytolbutamide (4-OH-TB) were purchased from Sigma–
Aldrich, USA. Nitrazepam was of BP reference standard. All
chemicals used were of the highest available commercial purity.
All the herbs were purchased in dry form from Saudi market.
General-purpose reagents (GPR) were used for extraction pro-
cesses, whileHPLCgrade solvents were used forHPLCdetermi-
nations. All other materials are of analytical grade.
2.2. Herb extraction
Each dried powdered herb (100 g) was exhaustively extracted
by cold maceration with ethanol for 5 days; extract was ﬁltered
and concentrated at 40 C under reduced pressure using a Bu-
chi rotatory evaporator. The concentrations of the produced
extracts to the weight of dried samples (% w/w) were found
to be 34.8 for boswellia, 24 for myrrh, 31.6 for asafoetida,
5.1 for curcuma, 6.4 for ginger, 38.7 for aloe, 6.2 for fenugreek,
11.2 for black seed, 7.5 for garden cress, 6.4 for cumin and 5.0
for aniseed. The extracts were serially diluted using 96% etha-
nol to produce stock solutions, which were kept in a refriger-
ator until used.
2.3. Microsomal incubation
Herbal alcoholic extracts were transferred to clean tubes and
alcohol was evaporated under nitrogen. Incubation conditions
were selected based on previous studies (Ho and Moody, 1993;
Miners et al., 1988) and preliminary experiments that involved
the use of different incubation times and different microsomal
protein concentrations. TB (5.0 ll of 15 mM to give a ﬁnal
concentration of 0.15 mM) was added to the tubes before the
addition of human liver microsomes (0.25 mg protein/ml ﬁnal
concentration) and potassium phosphate buffer (0.1 M, pH
7.4), then mixed gently, and pre-incubated in a shaker water
bath at 37 C for 3.0 min. The reaction was initiated by the
addition of 25 ll of 20 mM NADPH (1.0 mM ﬁnal concentra-
tion) to complete a ﬁnal volume of 0.5 ml, and incubated for a
further 30 min. Control samples were treated the same way ex-
cept that no herbal extracts were added. The reaction was ter-
minated by the addition of cold methanol (250 ll) with
vigorous shaking for 2.0 min. Nitrazepam (25 ll) from a stock
solution of 1.0 lg/ml was added as an internal standard to
each tube. The mixture was centrifuged at 12,000 rpm for
10 min; a 500 ll of the supernatant was transferred to HPLC
autosampler vial and 50 ll of that was injected for analysis.
Formation of the metabolite was found in the preliminary
experiments to be linear with respect to time and protein
concentration under the described conditions. Since it is
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Figure 1 Effects of different herbs (at a ﬁxed concentration) on
the formation of 4-OH-TB from tolbutamide in human liver
microsomes (mean + SD, *P< 0.05).
Effects of some commonly used Saudi folk herbal medications 169impossible to predict the concentrations of the herbal constit-
uents at the site of metabolism in vivo, the eleven herbs were
initially screened at a relatively high ﬁxed concentration
(25 lg/ml) and then herbs that showed greater than 20% mod-
ulation were further investigated at a lower range of
concentration.
2.4. Analysis of 4-hydroxytolbutamide (4-OH-TB) in human
liver microsomes
4-OH-TB in human liver microsomes was analyzed using previ-
ously published HPLC method with slight modiﬁcation (Miners
et al., 1988). A symmetry column (150 · 3.9 mm ID, 5.0 lm) pur-
chased from Waters, Milford Massachusetts, USA, was used
for this assay. Mobile phase consisted of acetonitrile: 0.05 M
potassium dihydrogen orthophosphate (30:70; pH adjusted to
3.4 with orthophosphoric acid). The ﬂow rate was 1 ml/min.
The detector was operated at ﬁxed wave length at 240 nm. Stock
solutions of tolbutamide, and 4-OH-TB were prepared in aceto-
nitrile and methanol; respectively. Calibration curve for tolbuta-
mide metabolite was constructed using a concentration range of
0.05–1.0 lg/ml. Each calibration curve was prepared to contain a
ﬁxed concentration of tolbutamide (0.15 mM), microsomes and
buffer but without the addition of NADPH.
2.5. Statistical analysis
Formation of 4-OH-TB in the presence of herbs was compared
to that of control using one-way analysis of variance (ANO-
VA), and a post hoc Tukey’s multiple comparison test, with
a P 6 0.05 considered signiﬁcant.
3. Results and discussion
In this in vitro microsomal study, boswellia, myrrh, asafoetida,
curcuma, ginger, aloe, fenugreek, black seed, garden cress, cu-
min and aniseed were investigated for their effects on the met-
abolic activity of one of the major drug metabolizing enzyme,
CYP2C9. Effects of the herbs were evaluated based on the for-
mation of CYP2C9-mediated 4-OH-TB from tolbutamide in
human liver microsomes.
Initially, a ﬁxed concentration of the eleven herbs (25
lg/ml) was used to evaluate the potential effects on CYP2C9
(Fig. 1). Herbs that produced greater than 20% modulation
in the formation of the metabolite were further evaluated at
a lower concentration range of the herbs. Based on that, cur-
cuma, ginger and aniseed were investigated at a concentration
range of 1.0–25 lg/ml. Curcuma produced a potent inhibition
on the metabolite formation and its maximum (about 45%
inhibition) was observed at the highest extract concentrations
(10 and 25 lg/ml) (Fig. 2). The maximum inhibition produced
by ginger was about 25% but it was not statistically signiﬁcant
(Fig. 3). On the other hand, aniseed signiﬁcantly activate the
formation of 4-OH-TB and the maximum activation (about
55%) was observed at 2.5 lg/ml of aniseed extract as depicted
in Fig. 4.
Although the use of alcoholic extracts provides a major
advantage in screening herbal products for drug interactions,
results obtained from such studies may not provide complete
information about the mechanisms of interactions. A major
reason for that is the presence of many herbal constituents ineach extract, which make it difﬁcult to relate an effect to cer-
tain compound(s). The observed inhibitory effect of CYP2C9
by curcuma is consistent with what has been reported by
Appiah-Opong et al. (2007). However, the experimental model
used in that study was based on recombinant CYP enzymes
that were individually expressed in Escherichia coli, instead
of human liver microsomes. They have shown signiﬁcant
inhibitory activities by the active ingredient of curcuma, cucu-
min, against ﬁve human CYP enzymes including CYP2C9,
which suggests that the observed curcuma effect in this study
is, at least partly, due to curcumin. The inhibition of CYP2C9
observed in their study suggests a non-competitive type of
inhibition.
Activation of CYP2C9-mediated reactions has been re-
ported in several previous studies (Korzekwa et al., 1998;
Hutzler et al., 2001, 2002, 2003; Tracy, 2006; Atkins et al.,
2001). However, activation of CYP2C9 by aniseed has not
been shown before. A possible mechanism for the cause of
CYP2C9 activation, which has been previously suggested by
several investigators, is the presence of multiple binding sites
in the enzyme active site (Korzekwa et al., 1998; Hutzler
et al., 2001, 2002, 2003; Tracy, 2006; Atkins et al., 2001). This
is supported by the fact that several CYP2C9 activators are
known to be also substrates of the enzyme. Based on this
hypothesis, the activation by aniseed observed in this study
could be due to the ability of one (or more) of aniseed constit-
uents to bind to a CYP2C9 binding site leading to an increase
in the rate of tolbutamide metabolism possibly by inducing
conformational changes in the enzyme. Constituents of aniseed
include anethole, estragole, coumarins and ﬂavonoids (Newall
et al., 1996). Since CYP2C9 substrates include coumarin deriv-
atives such as warfarin, some coumarin constituents in aniseed
may have the structural requirements for binding to CYP2C9
and modulating its metabolic activity. Further in vitro studies
that investigate the potential effects of individual aniseed con-
stituents would be helpful in understanding the mechanism of
CYP2C9 activation observed in this study.
It is concluded that among the eleven investigated herbs in
this study, only curcuma and aniseed were capable of signiﬁ-
cantly modulating CYP2C9 metabolic activity. These two
herbs therefore, have the potential to interact with conven-
tional medicines eliminated from the body by CYP2C9. Some
of these substrates such as S-warfarin and phenytoin are
known to have narrow therapeutic margins and therefore,
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Figure 2 Effect of curcuma on the formation of 4-OH-TB from
tolbutamide in human liver microsomes (mean + SD, *P< 0.05).
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Figure 3 Effect of ginger on the formation of 4-OH-TB from
tolbutamide in human liver microsomes (mean + SD).
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Figure 4 Effect of aniseed on the formation of 4-OH-TB from
tolbutamide in human liver microsomes (mean + SD, *P< 0.05).
170 F.I. Al-Jenoobiany alteration in their metabolism could result in serious
clinical consequences even at their normal therapeutic doses
(Gilbar and Brodribb, 2001; Murphy and Wilbur, 2003;
Suvarna et al., 2003).Acknowledgements
This study has been supported by the Deanship of Scientiﬁc
Research (Grant number: DSR-AR-2-20) and the College of
Pharmacy Research Center (Grant number CPRC-132), King
Saud University, Riyadh, Saudi Arabia.References
Al-Rowais, N.A., 2002. Herbal medicine in the treatment of diabetes
mellitus. Saudi Med. J. 23 (11), 1327–1331.
Appiah-Opong, R., Commandeur, J.N., Vugt-Lussenburg, B.V.,
Vermeulen, N.P., 2007. Inhibition of human recombinant cyto-chrome P450s by curcumin and curcumin decomposition products.
Toxicology 235, 83–91.
Atkins, W.M., Wang, R.W., Lu, A.H., 2001. Allosteric behavior in
cytochrome P450-dependent in vitro drug-drug interactions: a
prospective based on conformational dynamics. Chem. Res.
Toxicol. 14, 338–347.
Bailey, D.G., Dresser, G.K., 2004. Natural products and adverse drug
interactions. CMAJ 170, 1531–1532.
David, F.V., Sandeep, M., Maurice, D., 2002. Structure-activity
relationship for human cytochrome P450 substrates and inhibitors.
Drug Metab. Rev. 34, 69–82.
Diamond, B.J., Shifﬂett, S.C., Feiwel, N., 2000. Ginkgo biloba extract:
mechanisms and clinical indications. Arch. Phys. Med. Rehabilat.
81 (5), 668–678.
Eisenberg, D.M., Kessler, R.C., Foster, C., Norlock, F.E., Calkins,
D.R., Delbanco, T.L., 1993. Unconventional medicine in the
United States: prevalence, cost and patterns of use. N. Engl. J.
Med. 328 (4), 246–252.
Fisher, P., Ward, A., 1994. Complementary medicine in Europe. Br.
Med. J. 309 (6947), 107–111.
Fuhr, U., Muller-Peltzer, H., Kern, R., Lopez-Rojas, P., Junemann,
M., Harder, S., Staib, A.H., 2002. Effects of grapefruit juice and
smoking on verapamil concentrations in steady state. Eur. J. Clin.
Pharmacol. 58 (1), 45–53.
Galluzzi, S., Zanetti, O., Binetti, G., 2000. Coma in a patient with
Alzheimer’s disease taking low dose trazodone and ginkgo biloba.
J. Neurol. Neuro. Surg. Psychiatr. 68 (5), 679–683.
Gilbar, P.J., Brodribb, T.R., 2001. Phenytoin and ﬂuorouracil inter-
action. Ann. Pharmacother. 35, 1367–1370.
Goho, C., 2001. Oral midazolam grapefruit juice drug interaction.
Pediatr. Dent. 23 (4), 365–366.
Gross, A.S., Goh, Y.D., Addison, R.S., Shenﬁeld, G.M., 1999.
Inﬂuence of grapefruit juice on cisapride pharmacokinetics. Clin.
Pharmacol. Ther. 65 (4), 395–401.
Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry,
W.B., Ang, Y.W., 2002. Cytochrome P450 phenotypic ratios for
predicting herb-drug interactions in humans. Clin. Pharmacol.
Ther. 72 (3), 276–287.
Guyonnet, D., Belloir, C., Suscetet, M., Siess, M.H., Le Bon, A.M.,
2000. Liver subcellular fractions from rats treated by organosulfur
compounds from Alliummodulate mutagen activation. Mutat. Res.
466 (1), 17–26.
Hermann, M., Asberg, A., Reubsaet, J.L., Sather, S., Berg, K.J.,
Christensen, H., 2002. Intake of grapefruit juice alters the meta-
bolic pattern of cyclosporine in renal transplant recipients. Int.
Clin. Pharmacol. Ther. 40 (10), 451–456.
Hidaka, M., Nagata, M., Kawano, Y., Sekiya, H., Kai, H., Yamasaki,
K., Okumura, M., Arimori, K., 2008. Inhibitory effects of fruit
juices on cytochrome P450 2C9 activity in vitro. Biosci. Biotechnol.
Biochem. 72 (2), 406–411.
Ho, J.W., Moody, D.E., 1993. Determination of tolbutamide hydrox-
ylation in rat liver microsomes by high-performance liquid chro-
matography: effect of psychoactive drugs on in vitro activity. Life
Sci. 52 (1), 21–28.
Huang, S.M., Lesko, L.J., 2004. Drug–drug, drug-dietary supplement,
and drug-citrus fruit and other food interactions: what have we
learned? J. Clin. Pharmacol. 44 (6), 559–569.
Hutzler, J.M., Hauer, M.J., Tracy, T.S., 2001. Dapsone activation
of CYP2C9-mediated metabolism: evidence for activation of
multiple substrates and a two-site model. Drug Metab. Dispos.
29, 1–6.
Hutzler, J.M., Kolwankar, D., Hummel, M.A., Tracy, T.S., 2002.
Activation of CYP2C9-mediated metabolism by a series of dapsone
analogs: kinetics and structural requirements. Drug Metab. Dispos.
30 (11), 1194–1200.
Hutzler, J.M., Wienkers, L.C., Wahlstrom, J.L., Carlson, T.J., Tracy,
T.S., Hutzler, J.M., Wienkers, L.C., Wahlstrom, J.L., Carlson, T.J.,
Tracy, T.S., 2003. Activation of cytochrome P450 2C9-mediated
Effects of some commonly used Saudi folk herbal medications 171metabolism: mechanistic evidence in support of kinetic observa-
tions. Arch. Biochem. Biophys. 410 (1), 16–24.
Ioannides, C., 2002. Pharmacokinetic interactions between herbal
remedies and medicinal drug. Xenobiotica 32 (6), 451–478.
Ishihara, K., Kushida, H., Yuzurihara, M., Wakui, Y., Yanagisawa,
T., Kamei, H., Ohmori, S., Kitada, M., 2000. Interaction of drugs
and Chinese herbs: pharmacokinetic changes of tolbutamide and
diazepam caused by extract of Angelica dahurica. J. Pharm.
Pharmacol. 52 (8), 1023–1029.
Izzo, A.A., Ernst, E., 2001. Interactions between herbal medicine-sand
prescribed drug: a systematic review. Drugs 61 (15), 2163–2175.
Jankel, C.A., Fitterman, L.K., 1993. Epidemiology of drug–drug
interactions as a cause of hospital admissions. Drug Safety 9 (1),
51–59.
Klepser, T.B., Klepser, M.E., 1999. Unsafe and potentially safe herbal
therapies. Am. J. Health Syst. Pharm. 56 (2), 125–138.
Korzekwa, K.R., Krishnamachary, N., Shou, M., Ogai, A., Parise,
R.A., Rettie, A.E., Gonzalez, F.J., Tracy, T.S., 1998. Evaluation of
atypical cytochrome P450 kinetics with two-substrate models:
evidence that multiple substrates can simultaneously bind to
cytochrome P450 active sites. Biochemistry 37 (12), 4137–4147.
Lee, C.R., Goldstein, J.A., Pieper, J.A., 2002. Cytochrome P4502C9
polymorphisms: a comprehensive review of the in vitro and human
data. Pharmacogenetics 12, 251–263.
Libersa, C.C., Brique, S.A., Motte, K.B., Caron, J.F., Guedon-
Moreau, L.M., Humber, L., Vincent, A., Devos, P., Lhermitte,
M.A., 2000. Dramatic inhibition of amiodarone metabolism
induced by grapefruit juice. Br. J. Clin. Pharmacol. 49 (4), 373–378.
Lilja, J.J., Kivisto, K.T., Neuvonen, P.J., 2000. Duration of effect of
grapefruit juice on the pharmacokinetics of the CYP3A4 substrate
simvastatin. Clin. Pharmacol. Ther. 68 (4), 384–390.
Maclennan, A.H., Wilson, D.H., Taylor, A.W., 1996. Prevalence and
cost of alternative medicine in Australia. Lancet 347 (9001), 569–573.Miners, J.O., Smith, K.J., Robson, R.A., McManus, M.E., Veronese,
M.E., Birkett, D.J., 1988. Tolbutamide hydroxylation by human
liver microsomes: kinetic characterization and relationship to other
cytochrome P-450 dependent xenobiotic oxidations. Biochem.
Pharmacol. 37, 1137–1144.
Murphy, A., Wilbur, K., 2003. Phenytoin–diazepam interaction. Ann.
Pharmacother. 37, 659–663.
Nagata, M., Hidaka, M., Sekiya, H., Kawano, Y., Yamasaki, K.,
Okumura, M., Arimori, K., 2007. Effects of pomegranate juice on
human cytochrome P450 2C9 and tolbutamide pharmacokinetics in
rats. Drug Metab. Dispos. 35 (2), 302–305.
Newall, C.A., Anderson, L.A., Phillipson, J.D., 1996. Herbal Medi-
cines. Pharmaceutical Press, London, England, pp. 30–31.
Sugiyama, T., Kubota, Y., Shinozuka, K., Yamada, S., Wu, J.,
Umegaki, K., 2004. Ginkgo biloba extract modiﬁes hypo-
glycemic action of tolbutamide via hepatic cytochrome P450
mediated mechanism in aged rats. Life Sci. 75 (9), 1113–
1122.
Suvarna, R., Pirmohamed, M., Henderson, L., 2003. Possible inter-
action between warfarin and cranberry juice. BMJ 327, 1454.
Tracy, T.S., 2006. Atypical cytochrome p450 kinetics: implications for
drug discovery. Drugs R.D 7, 349–363.
Yang, C.S., Chhabra, S.K., Hong, J.Y., Smith, T.J., 2001. Mechanisms
of inhibition of chemical toxicity and carcinogenesis by diallyl
sulﬁde (DAS) and related compound. J. Nutr. 131 (3s), 1041S–
1045S.
Yeung, J.H., Chan, S.L., Or, P.M., 2006. Polysaccharide peptides from
COV-1 strain of Coriolus versicolor inhibit tolbutamide 4-hydrox-
ylation in the rat in vitro and in vivo. Food Chem. Toxicol. 44 (8),
1414–1423.
Zhou, S., Chan, E., Pan, S.Q., Huang, M., Lee, E.J., 2004. Pharma-
cokinetic interactions of drugs with St. John’s Wort. J. Psychphar-
macol. 18 (2), 262–276.
